Expedition Therapeutics raised $115 million in a Series B financing led by General Atlantic to advance its COPD program, EXPD-101, through ongoing Phase 2 evaluation. The company said the funding supports clinical, regulatory, and operational expansion as it prepares additional development milestones. Mironid also secured new capital, pulling in a $46 million Series B as its lead small molecule MR-L45 enters clinical development for autosomal dominant polycystic kidney disease. The round aims to fund MR-L45’s path through early clinical phases. Together, the rounds underscore that investors are continuing to fund differentiated approaches in high-burden respiratory and rare kidney diseases, even as mid-stage biotech risk remains elevated.